Table Graph
      published meta-analysis   sensitivity analysis   studies

anticoagulant in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsINSPIRATION, 2021 1.09 [0.78; 1.53] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] 1.08[0.89; 1.32]INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202120%1,660moderatenot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] 0.83[0.67; 1.03]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,074NAnot evaluable Major thrombotic events or deathdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 1.04[0.80; 1.36]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,091NAnot evaluable Major bleedingdetailed resultsINSPIRATION, 2021 1.83 [0.53; 6.34] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.56[0.85; 2.87]INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202120%1,653moderatenot evaluable Thromboembolic eventsdetailed resultsINSPIRATION, 2021 1.07 [0.76; 1.49] 1.07[0.76; 1.49]INSPIRATION, 202110%562NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-18 23:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 608,830,831,829,901,680,595,828,681,1209,833 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons